Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,200.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,200.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,200.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $3,200.0012/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673847431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

357 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,055.75 12/31/2020 Non-covered Recipient Entity
Shelly David Senders, Md, Inc
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 736744485
Principal investigator 1 AstraZeneca Pharmaceuticals LP $540.98 12/31/2020 Non-covered Recipient Entity
Shelly David Senders, Md, Inc
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). No dispute reported 06/30/2026 736748423
Principal investigator 1 Merck Sharp & Dohme Corporation $8,899.80 12/29/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723219
Principal investigator 1 PFIZER INC. $155,942.95 12/29/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742899251
Principal investigator 1 PFIZER INC. $48,101.87 12/19/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742899201
Principal investigator 1 PFIZER INC. $1,285.00 12/17/2020 Non-covered Recipient Entity
Shelly David Senders MC Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870583
Principal investigator 1 PFIZER INC. $8,016.04 12/15/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742899151
Principal investigator 1 SANOFI PASTEUR INC. $4,475.00 12/15/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030143
Principal investigator 1 PFIZER INC. $15,379.95 12/12/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742899195
Principal investigator 1 PFIZER INC. $104.00 12/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868069
Principal investigator 1 PFIZER INC. $791.70 12/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868248
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702561
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702563
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702565
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702567
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702569
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702571
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702883
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702885
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702887
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702889
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702891
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702929
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702931
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702933
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702935
Principal investigator 1 Merck Sharp & Dohme Corporation $11.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702939
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702973
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702975
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702977
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702979
Principal investigator 1 Merck Sharp & Dohme Corporation $2.72 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702981
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740702983
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703095
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703097
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703099
Principal investigator 1 Merck Sharp & Dohme Corporation $0.76 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703101
Principal investigator 1 Merck Sharp & Dohme Corporation $1.52 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703135
Principal investigator 1 Merck Sharp & Dohme Corporation $1.52 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703137
Principal investigator 1 Merck Sharp & Dohme Corporation $11.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703139
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703141
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703143
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703145
Principal investigator 1 Merck Sharp & Dohme Corporation $16.16 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703179
Principal investigator 1 Merck Sharp & Dohme Corporation $16.16 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703181
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703183
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703185
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703187
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703189
Principal investigator 1 Merck Sharp & Dohme Corporation $2.72 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703227
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703229
Principal investigator 1 Merck Sharp & Dohme Corporation $19.36 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703231
Principal investigator 1 Merck Sharp & Dohme Corporation $19.36 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703233
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703235
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 12/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703237
Principal investigator 1 PFIZER INC. $26,071.04 12/05/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742899197
Principal investigator 1 PFIZER INC. $2,412.50 12/03/2020 Non-covered Recipient Entity
Shelly David Senders MC Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870177
Principal investigator 1 PFIZER INC. $13,055.00 12/02/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742899095
Principal investigator 1 Merck Sharp & Dohme Corporation $23,587.20 12/01/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723217
Principal investigator 1 PFIZER INC. $22,342.12 11/28/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915295
Principal investigator 1 PFIZER INC. $475.02 11/23/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868075
Principal investigator 1 PFIZER INC. $62.40 11/23/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868251
Principal investigator 1 PFIZER INC. $23,466.46 11/21/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915291
Principal investigator 1 PFIZER INC. $6,188.30 11/20/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863611
Principal investigator 1 SANOFI PASTEUR INC. $4,275.00 11/19/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030133
Principal investigator 1 PFIZER INC. $20,551.10 11/17/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915297
Principal investigator 1 Merck Sharp & Dohme Corporation $2,649.60 11/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723215
Principal investigator 1 PFIZER INC. $2,678.00 11/16/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870977
Principal investigator 1 PFIZER INC. $475.02 11/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868073
Principal investigator 1 PFIZER INC. $62.40 11/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868339
Principal investigator 1 PFIZER INC. $37,288.35 11/07/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915365
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 11/06/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702937
Principal investigator 1 Merck Sharp & Dohme Corporation $406.00 11/03/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703091
Principal investigator 1 PFIZER INC. $55,734.68 10/31/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915775
Principal investigator 1 Merck Sharp & Dohme Corporation $23,969.40 10/29/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703529
Principal investigator 1 PFIZER INC. $5,086.32 10/28/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863339
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 10/27/2020 Non-covered Recipient Entity
SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 753908583
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 10/27/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965522853
Recipient PFIZER INC. $940.00 10/25/2020 Covered Recipient Physician PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 742862187
Principal investigator 1 PFIZER INC. $39,285.58 10/23/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915779
Principal investigator 1 PFIZER INC. $104.00 10/21/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868253
Principal investigator 1 PFIZER INC. $791.70 10/21/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868347
Principal investigator 1 SANOFI PASTEUR INC. $11,970.00 10/20/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030115
Principal investigator 1 PFIZER INC. $2,036.25 10/17/2020 Non-covered Recipient Entity
Shelly David Senders MC Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870181
Principal investigator 1 PFIZER INC. $15,090.20 10/16/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863257
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 10/08/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744030123
Principal investigator 1 Merck Sharp & Dohme Corporation $18,052.80 10/07/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723213
Principal investigator 1 PFIZER INC. $32,942.04 10/07/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915781
Principal investigator 1 PFIZER INC. $52.00 10/05/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742867781
Principal investigator 1 PFIZER INC. $395.85 10/05/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742868343
Principal investigator 1 PFIZER INC. $19,565.00 10/02/2020 Non-covered Recipient Entity
Shelly David Senders MC Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742870263
Principal investigator 1 PFIZER INC. $39,583.68 10/02/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742915713
Principal investigator 1 PFIZER INC. $3,984.34 10/01/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863261
Principal investigator 1 PFIZER INC. $395.85 09/28/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863609
Principal investigator 1 PFIZER INC. $52.00 09/28/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864661
Principal investigator 1 PFIZER INC. $67,430.34 09/26/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948953
Principal investigator 1 Merck Sharp & Dohme Corporation $27,955.20 09/24/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723453
Principal investigator 1 SANOFI PASTEUR INC. $4,275.00 09/22/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030105
Principal investigator 1 PFIZER INC. $316.68 09/21/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864345
Principal investigator 1 PFIZER INC. $41.60 09/21/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864449
Principal investigator 1 PFIZER INC. $3,000.00 09/19/2020 Non-covered Recipient Entity
Shelly David Senders MC Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742869317
Principal investigator 1 PFIZER INC. $55,220.26 09/19/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742949307
Principal investigator 1 PFIZER INC. $24,246.92 09/17/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863253
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 09/14/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703093
Principal investigator 1 PFIZER INC. $63,959.10 09/12/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742949313
Principal investigator 1 Merck Sharp & Dohme Corporation $1,421.00 09/11/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702879
Principal investigator 1 PFIZER INC. $76,750.92 09/10/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742948955
Principal investigator 1 PFIZER INC. $475.02 09/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862035
Principal investigator 1 PFIZER INC. $62.40 09/09/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864667
Principal investigator 1 Merck Sharp & Dohme Corporation $106.08 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702871
Principal investigator 1 Merck Sharp & Dohme Corporation $563.94 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702963
Principal investigator 1 Merck Sharp & Dohme Corporation $609.00 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702967
Principal investigator 1 Merck Sharp & Dohme Corporation $92.94 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703011
Principal investigator 1 Merck Sharp & Dohme Corporation $182.16 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703533
Principal investigator 1 Merck Sharp & Dohme Corporation $149.04 08/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703559
Principal investigator 1 PFIZER INC. $4,500.00 08/29/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742877875
Principal investigator 1 PFIZER INC. $23,451.67 08/29/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742949309
Principal investigator 1 PFIZER INC. $4,961.00 08/28/2020 Non-covered Recipient Entity
Shelly David Senders MD inc dba Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863357
Principal investigator 1 PFIZER INC. $83.20 08/25/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862205
Principal investigator 1 PFIZER INC. $633.36 08/25/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864443
Principal investigator 1 Merck Sharp & Dohme Corporation $16,871.40 08/20/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723411
Principal investigator 1 SANOFI PASTEUR INC. $9,450.00 08/20/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030095
Principal investigator 1 Merck Sharp & Dohme Corporation $7,741.20 08/14/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723069
Principal investigator 1 PFIZER INC. $316.68 08/10/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864337
Principal investigator 1 PFIZER INC. $41.60 08/10/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864663
Principal investigator 1 PFIZER INC. $9,500.00 08/04/2020 Non-covered Recipient Entity
Shelly David Senders MD Inc dba Senders Pediatrics
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742949003
Principal investigator 1 PFIZER INC. $1,339.00 07/29/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742869313
Principal investigator 1 Merck Sharp & Dohme Corporation $558.00 07/28/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723055
Principal investigator 1 PFIZER INC. $158.34 07/28/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863513
Principal investigator 1 PFIZER INC. $20.80 07/28/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864447
Principal investigator 1 PFIZER INC. $20.80 07/27/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862027
Principal investigator 1 PFIZER INC. $158.34 07/27/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862201
Principal investigator 1 PFIZER INC. $669.50 07/27/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742869247
Principal investigator 1 Merck Sharp & Dohme Corporation $16,872.60 07/23/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703453
Principal investigator 1 PFIZER INC. $669.50 07/21/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742869310
Principal investigator 1 SANOFI PASTEUR INC. $14,296.00 07/21/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030083
Principal investigator 1 Merck Sharp & Dohme Corporation $92.94 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702893
Principal investigator 1 Merck Sharp & Dohme Corporation $149.04 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702921
Principal investigator 1 Merck Sharp & Dohme Corporation $563.94 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702927
Principal investigator 1 Merck Sharp & Dohme Corporation $812.00 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703005
Principal investigator 1 Merck Sharp & Dohme Corporation $106.08 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703057
Principal investigator 1 Merck Sharp & Dohme Corporation $182.16 07/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703565
Principal investigator 1 Merck Sharp & Dohme Corporation $5,284.80 07/15/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722739
Principal investigator 1 PFIZER INC. $20.80 07/15/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742862031
Principal investigator 1 PFIZER INC. $158.34 07/15/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863517
Principal investigator 1 SANOFI PASTEUR INC. $1,399.00 07/14/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744030073
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703459
Principal investigator 1 Merck Sharp & Dohme Corporation $206.25 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703461
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703463
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703489
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703491
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703493
Principal investigator 1 Merck Sharp & Dohme Corporation $51.00 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703495
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703497
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703499
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703523
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703525
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 07/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740703527
Principal investigator 1 PFIZER INC. $475.02 07/06/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742863605
Principal investigator 1 PFIZER INC. $62.40 07/06/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 742864341
Principal investigator 1 Merck Sharp & Dohme Corporation $406.00 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702919
Principal investigator 1 Merck Sharp & Dohme Corporation $563.94 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702961
Principal investigator 1 Merck Sharp & Dohme Corporation $92.94 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703009
Principal investigator 1 Merck Sharp & Dohme Corporation $182.16 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703531
Principal investigator 1 Merck Sharp & Dohme Corporation $149.04 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703557
Principal investigator 1 Merck Sharp & Dohme Corporation $106.08 07/04/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703567
Principal investigator 1 PFIZER INC. $2,678.00 07/01/2020 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 742869251
Principal investigator 1 Merck Sharp & Dohme Corporation $21,259.20 06/25/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703455
Principal investigator 1 SANOFI PASTEUR INC. $15,428.00 06/18/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030063
Principal investigator 1 Merck Sharp & Dohme Corporation $124.20 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702877
Principal investigator 1 Merck Sharp & Dohme Corporation $406.00 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702917
Principal investigator 1 Merck Sharp & Dohme Corporation $469.95 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702923
Principal investigator 1 Merck Sharp & Dohme Corporation $88.40 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703007
Principal investigator 1 Merck Sharp & Dohme Corporation $232.35 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703047
Principal investigator 1 Merck Sharp & Dohme Corporation $151.80 06/16/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703561
Principal investigator 1 Merck Sharp & Dohme Corporation $12,598.80 06/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723399
Principal investigator 1 Merck Sharp & Dohme Corporation $302.94 06/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703051
Principal investigator 1 Merck Sharp & Dohme Corporation $33.06 06/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703053
Principal investigator 1 SANOFI PASTEUR INC. $900.00 06/09/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744030051
Principal investigator 1 Merck Sharp & Dohme Corporation $108.43 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702873
Principal investigator 1 Merck Sharp & Dohme Corporation $123.76 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702875
Principal investigator 1 Merck Sharp & Dohme Corporation $657.93 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702969
Principal investigator 1 Merck Sharp & Dohme Corporation $812.00 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702971
Principal investigator 1 Merck Sharp & Dohme Corporation $212.52 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703015
Principal investigator 1 Merck Sharp & Dohme Corporation $173.88 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703563
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722733
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723059
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723065
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723101
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723155
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723203
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723207
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723255
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723261
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723303
Principal investigator 1 Merck Sharp & Dohme Corporation $51.00 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723353
Principal investigator 1 Merck Sharp & Dohme Corporation $206.25 06/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723359
Principal investigator 1 PFIZER INC. $12,724.20 06/04/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 742934709
Principal investigator 1 Merck Sharp & Dohme Corporation $29,176.20 05/28/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703457
Principal investigator 1 SANOFI PASTEUR INC. $1,800.00 05/19/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744030039
Principal investigator 1 Merck Sharp & Dohme Corporation $49.68 05/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702925
Principal investigator 1 Merck Sharp & Dohme Corporation $60.72 05/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702965
Principal investigator 1 Merck Sharp & Dohme Corporation $187.98 05/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703013
Principal investigator 1 Merck Sharp & Dohme Corporation $30.98 05/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703049
Principal investigator 1 Merck Sharp & Dohme Corporation $35.36 05/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740703055
Principal investigator 1 Merck Sharp & Dohme Corporation $6,457.20 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722729
Principal investigator 1 Merck Sharp & Dohme Corporation $23.75 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722731
Principal investigator 1 Merck Sharp & Dohme Corporation $3.25 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722737
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722741
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723057
Principal investigator 1 Merck Sharp & Dohme Corporation $17.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723103
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723105
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723107
Principal investigator 1 Merck Sharp & Dohme Corporation $1.75 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723109
Principal investigator 1 Merck Sharp & Dohme Corporation $10.65 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723111
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723153
Principal investigator 1 Merck Sharp & Dohme Corporation $660.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723157
Principal investigator 1 Merck Sharp & Dohme Corporation $68.75 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723159
Principal investigator 1 Merck Sharp & Dohme Corporation $7.04 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723161
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723201
Principal investigator 1 Merck Sharp & Dohme Corporation $8.25 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723209
Principal investigator 1 Merck Sharp & Dohme Corporation $84.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723211
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723253
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723259
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723301
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723305
Principal investigator 1 Merck Sharp & Dohme Corporation $302.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723307
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723311
Principal investigator 1 Merck Sharp & Dohme Corporation $51.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723351
Principal investigator 1 Merck Sharp & Dohme Corporation $206.25 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723357
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723401
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723405
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723409
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723455
Principal investigator 1 Merck Sharp & Dohme Corporation $131.78 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723457
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723459
Principal investigator 1 Merck Sharp & Dohme Corporation $2.50 05/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723461
Principal investigator 1 SANOFI PASTEUR INC. $15,515.00 05/07/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030021
Principal investigator 1 Merck Sharp & Dohme Corporation $21,450.60 04/30/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723699
Principal investigator 1 Merck Sharp & Dohme Corporation $558.00 04/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723053
Principal investigator 1 Merck Sharp & Dohme Corporation $406.00 04/24/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740702881
Principal investigator 1 SANOFI PASTEUR INC. $12,408.00 04/21/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744030013
Principal investigator 1 Merck Sharp & Dohme Corporation $11,647.20 04/17/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723051
Principal investigator 1 SANOFI PASTEUR INC. $12,290.00 04/16/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744029927
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722735
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723061
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723063
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723067
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723151
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723205
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723251
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723257
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723309
Principal investigator 1 Merck Sharp & Dohme Corporation $51.00 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723349
Principal investigator 1 Merck Sharp & Dohme Corporation $206.25 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723355
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723403
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 04/08/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723407
Principal investigator 1 Merck Sharp & Dohme Corporation $5,737.20 03/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723735
Principal investigator 1 Merck Sharp & Dohme Corporation $45,286.80 03/26/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723703
Principal investigator 1 PFIZER INC. $546.26 03/26/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 742934299
Principal investigator 1 SANOFI PASTEUR INC. $44,730.00 03/19/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744029915
Principal investigator 1 GlaxoSmithKline, LLC. $1,051.20 03/18/2020 Non-covered Recipient Entity
SHELLY DAVID SENDERS MD INC
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 753908849
Principal investigator 1 GlaxoSmithKline, LLC. $1,051.20 03/18/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965522851
Principal investigator 1 Merck Sharp & Dohme Corporation $144.99 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723071
Principal investigator 1 Merck Sharp & Dohme Corporation $169.74 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723117
Principal investigator 1 Merck Sharp & Dohme Corporation $231.93 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723119
Principal investigator 1 Merck Sharp & Dohme Corporation $233.01 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723121
Principal investigator 1 Merck Sharp & Dohme Corporation $259.74 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723123
Principal investigator 1 Merck Sharp & Dohme Corporation $386.34 03/18/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723163
Principal investigator 1 SANOFI PASTEUR INC. $4,500.00 03/17/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen No dispute reported 06/30/2026 744029895
Principal investigator 1 SANOFI PASTEUR INC. $17,541.00 03/17/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744029905
Principal investigator 1 Merck Sharp & Dohme Corporation $22,862.40 03/11/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723731
Principal investigator 1 Merck Sharp & Dohme Corporation $96.90 03/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723073
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 03/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723167
Principal investigator 1 Merck Sharp & Dohme Corporation $76.70 03/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723171
Principal investigator 1 Merck Sharp & Dohme Corporation $772.68 03/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723173
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722719
Principal investigator 1 Merck Sharp & Dohme Corporation $3.60 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723045
Principal investigator 1 Merck Sharp & Dohme Corporation $5.25 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723149
Principal investigator 1 Merck Sharp & Dohme Corporation $53.04 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723189
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723195
Principal investigator 1 Merck Sharp & Dohme Corporation $71.25 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723197
Principal investigator 1 Merck Sharp & Dohme Corporation $9.75 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723199
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723239
Principal investigator 1 Merck Sharp & Dohme Corporation $1,980.00 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723291
Principal investigator 1 Merck Sharp & Dohme Corporation $12.12 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723341
Principal investigator 1 Merck Sharp & Dohme Corporation $14.52 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723397
Principal investigator 1 Merck Sharp & Dohme Corporation $252.00 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723443
Principal investigator 1 Merck Sharp & Dohme Corporation $29.64 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723449
Principal investigator 1 Merck Sharp & Dohme Corporation $214.50 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723773
Principal investigator 1 Merck Sharp & Dohme Corporation $24.75 03/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723775
Principal investigator 1 Merck Sharp & Dohme Corporation $42,643.80 02/25/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723701
Principal investigator 1 PFIZER INC. $1,365.65 02/25/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 742935175
Principal investigator 1 SANOFI PASTEUR INC. $13,234.00 02/13/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744029883
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722723
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722725
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723039
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723041
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723089
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723091
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723095
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723097
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723139
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723141
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723147
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723193
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723241
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723243
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723245
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723297
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723337
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723339
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723345
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723391
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723393
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723439
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723445
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723767
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723769
Principal investigator 1 Merck Sharp & Dohme Corporation $21.30 02/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723771
Principal investigator 1 Merck Sharp & Dohme Corporation $7,275.60 02/07/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723737
Principal investigator 1 Merck Sharp & Dohme Corporation $974.79 01/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723113
Principal investigator 1 Merck Sharp & Dohme Corporation $145.35 01/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723115
Principal investigator 1 Merck Sharp & Dohme Corporation $46.02 01/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723165
Principal investigator 1 Merck Sharp & Dohme Corporation $579.51 01/27/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723169
Principal investigator 1 Merck Sharp & Dohme Corporation $46,204.80 01/23/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723705
Principal investigator 1 PFIZER INC. $2,731.30 01/17/2020 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS No dispute reported 06/30/2026 742937545
Principal investigator 1 Merck Sharp & Dohme Corporation $3,936.60 01/15/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723733
Principal investigator 1 SANOFI PASTEUR INC. $5,933.00 01/14/2020 Non-covered Recipient Entity
Dr Shelly David Senders,MD,Inc DBA Senders Pediatrics
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744029871
Principal investigator 1 Merck Sharp & Dohme Corporation $17,131.20 01/10/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723739
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722721
Principal investigator 1 Merck Sharp & Dohme Corporation $15.20 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740722727
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723043
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723047
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723049
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723093
Principal investigator 1 Merck Sharp & Dohme Corporation $484.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723099
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723143
Principal investigator 1 Merck Sharp & Dohme Corporation $5.20 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723145
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723191
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723247
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723249
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723289
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723293
Principal investigator 1 Merck Sharp & Dohme Corporation $1,056.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723295
Principal investigator 1 Merck Sharp & Dohme Corporation $110.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723299
Principal investigator 1 Merck Sharp & Dohme Corporation $13.20 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723343
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723347
Principal investigator 1 Merck Sharp & Dohme Corporation $134.40 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723389
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723395
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723441
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723447
Principal investigator 1 Merck Sharp & Dohme Corporation $744.00 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 740723451
Principal investigator 1 Merck Sharp & Dohme Corporation $2.80 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723741
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 01/09/2020 Non-covered Recipient Entity
SENDERS PEDIATRICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740723777
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,371.00 01/02/2020 Non-covered Recipient Entity
Shelly David Senders, Md, Inc
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). No dispute reported 06/30/2026 736747631
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,851.10 01/02/2020 Non-covered Recipient Entity
Shelly David Senders, Md, Inc
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 736749445